TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures
Brief Summary: The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.


Options:
A: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day
B: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
C: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250
D: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures
Brief Summary: The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.


Options:
A: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day
B: Arm Label: lamotrigine 300; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 300 mg/day | Arm Label: lamotrigine 250; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, 250 mg/day | Intervention Type: DRUG; Name: lamotrigine, 300 mg/day; Assigned to Arm(s): lamotrigine 300 | Intervention Type: DRUG; Name: lamotrigine, 250 mg/day; Assigned to Arm(s): lamotrigine 250
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Oxcarbazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine
D: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immune Responses Following One Versus Two Doses of Killed Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India
Brief Summary: The purpose of this study is to compare the safety and immunogenicity of one and two doses of the killed oral cholera vaccine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: bivalent killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: bivalent killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Killed bivalent whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli Placebo | Intervention Type: BIOLOGICAL; Name: Killed bivalent whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli Placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Injection | Arm Label: TA-CD Vaccination; Type: EXPERIMENTAL; Interventions: Drug: TA-CD Vaccination | Intervention Type: DRUG; Name: TA-CD Vaccination; Assigned to Arm(s): TA-CD Vaccination | Intervention Type: OTHER; Name: Placebo Injection; Assigned to Arm(s): Placebo injection
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medium-Dose UVA1 Versus Narrow-Band UVB Phototherapy: A Randomized Double-Blind Controlled Cross-Over-Study
Brief Summary: Atopic dermatitis (AD) is a very common disorder that is characterized by pruritic inflammatory skin lesions, with patients usually having an individual or family history of atopic diseases in their background. Phototherapy is among the first-line approaches in the management of AD. In this context, a variety of studies have shown a beneficial effect of natural or artificial UV radiation in atopic dermatitis (AD). The past ten years have seen the introduction of new phototherapeutic regimens for AD, including UVA1 and NB-UVB.UVA1 seems to be more effective than the above mentioned broadband spectra, in particular in acute severe AD. The aim of the present study is the comparison of UVA1 and NB-UVB phototherapy in the treatment of AD. Additionally, the course of several cytokines, human beta-defensins, and SMAD-proteins will be evaluated during the course of treatment.


Options:
A: Arm Label: Cholecalciferol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Placebo of cholecalciferol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of cholecalciferol | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo of cholecalciferol; Assigned to Arm(s): Placebo of cholecalciferol
B: Arm Label: Domestic ion-exchange water softener; Type: EXPERIMENTAL; Interventions: Device: Domestic ion-exchange water softener | Arm Label: Usual hard water supply; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Domestic ion-exchange water softener; Assigned to Arm(s): Domestic ion-exchange water softener
C: Arm Label: A: UVA1; Type: EXPERIMENTAL; Interventions: Procedure: UVA1 phototherapy | Arm Label: B: NB UVB; Type: EXPERIMENTAL; Interventions: Procedure: NB-UVB phototherapy | Intervention Type: PROCEDURE; Name: UVA1 phototherapy; Assigned to Arm(s): A: UVA1 | Intervention Type: PROCEDURE; Name: NB-UVB phototherapy; Assigned to Arm(s): B: NB UVB
D: Arm Label: Prevalent case of atopic dermatitis; Type: N/A; Interventions: Other: No intervention | Arm Label: Controls; Type: N/A; Interventions: Other: No intervention | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Controls, Prevalent case of atopic dermatitis

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Respiratory Muscle Training in Ventilator Dependent Patients
Brief Summary: The purpose of this study is to determine if inspiratory muscle strength training will increase the proportion of ventilator dependent patients weaned versus Sham treated patients.


Options:
A: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Other: Manual Diaphragm release technique (sham) | Arm Label: Intevention Group; Type: EXPERIMENTAL; Interventions: Other: Manual Diaphragm Release Technique | Intervention Type: OTHER; Name: Manual Diaphragm Release Technique; Assigned to Arm(s): Intevention Group | Intervention Type: OTHER; Name: Manual Diaphragm release technique (sham); Assigned to Arm(s): Control Group
B: Intervention Type: OTHER; Name: inspiratory muscle training; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: inspiratory muscle strength training; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Respiratory Muscle Training in Ventilator Dependent Patients
Brief Summary: The purpose of this study is to determine if inspiratory muscle strength training will increase the proportion of ventilator dependent patients weaned versus Sham treated patients.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: IgM-enriched Intravenous Immunoglobulins; Type: ACTIVE_COMPARATOR; Interventions: Drug: IgM-enriched Intravenous Immunoglobulins | Arm Label: Human Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: IgM-enriched Intravenous Immunoglobulins; Assigned to Arm(s): IgM-enriched Intravenous Immunoglobulins | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin
C: Intervention Type: PROCEDURE; Name: inspiratory muscle strength training; Assigned to Arm(s): N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial
Brief Summary: This study aimed to evaluate the efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome (CAS).


Options:
A: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo pill
B: Arm Label: Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical therapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Psychotherapy | Intervention Type: DRUG; Name: Medical therapy; Assigned to Arm(s): Control
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI) | Intervention Type: OTHER; Name: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI); Assigned to Arm(s): Intervention group
D: Arm Label: SMT-enhanced Cardiac Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: SMT-enhanced Cardiac Rehabilitation | Arm Label: Standard Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: SMT-enhanced Cardiac Rehabilitation; Assigned to Arm(s): SMT-enhanced Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Standard Cardiac Rehabilitation; Assigned to Arm(s): Standard Cardiac Rehabilitation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized, Double-blinded Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants
Brief Summary: It shall be investigated whether ventilated neonates and infants with a remifentanyl based analgesia and sedation can be extubated faster after discontinuation of the opioid infusion compared to neonates and infants with a fentanyl based analgesia and sedation.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Remifentanyl | Intervention Type: DRUG; Name: Remifentanyl; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): 2
B: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
C: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group
D: Arm Label: fentanyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 5% glucose solution | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): fentanyl | Intervention Type: DRUG; Name: 5% glucose solution; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
Brief Summary: The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.


Options:
A: Arm Label: Bupropion Arm; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation intervention, Drug: bupropion hydrochloride, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Other: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care | Arm Label: Health Education Arm; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: smoking cessation intervention, Genetic: gene expression analysis, Genetic: polymerase chain reaction, Other: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion Arm, Health Education Arm | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Bupropion Arm | Intervention Type: GENETIC; Name: gene expression analysis; Assigned to Arm(s): Bupropion Arm, Health Education Arm | Intervention Type: GENETIC; Name: polymerase chain reaction; Assigned to Arm(s): Bupropion Arm, Health Education Arm | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Bupropion Arm, Health Education Arm | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Bupropion Arm, Health Education Arm | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): Bupropion Arm, Health Education Arm
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion + Naltrexone | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bupropion + Naltrexone; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patch | Arm Label: Placebo Patch and Placebo Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Patch and Placebo Pill | Arm Label: Delayed-quit control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch | Intervention Type: DRUG; Name: Placebo Patch and Placebo Pill; Assigned to Arm(s): Placebo Patch and Placebo Pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
Brief Summary: The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion + Naltrexone | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bupropion + Naltrexone; Assigned to Arm(s): 2
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects
Brief Summary: The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
C: Arm Label: Glycopyrronium bromide; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects
Brief Summary: The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Fluticasone 500mcg BD via accuhaler or identical placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: D